These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 36384307)

  • 1. Understanding subjective experience in psychedelic-assisted psychotherapy: The need for phenomenology.
    Miceli McMillan R; Fernandez AV
    Aust N Z J Psychiatry; 2023 Jun; 57(6):783-788. PubMed ID: 36384307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
    Majić T; Schmidt TT; Gallinat J
    J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letter to the editor regarding "Understanding subjective experience in psychedelic-assisted psychotherapy: The need for phenomenology".
    Ventura B
    Aust N Z J Psychiatry; 2024 Jan; 58(1):92-93. PubMed ID: 37767966
    [No Abstract]   [Full Text] [Related]  

  • 4. Psilocybin occasioned mystical-type experiences.
    James E; Robertshaw TL; Hoskins M; Sessa B
    Hum Psychopharmacol; 2020 Sep; 35(5):e2742. PubMed ID: 32573835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Author reply to Letter to the Editor regarding 'Understanding subjective experience in psychedelic-assisted psychotherapy: The need for phenomenology'.
    Miceli McMillan R; Fernandez AV
    Aust N Z J Psychiatry; 2024 Jan; 58(1):93-94. PubMed ID: 37927156
    [No Abstract]   [Full Text] [Related]  

  • 6. Prescribing meaning: hedonistic perspectives on the therapeutic use of psychedelic-assisted meaning enhancement.
    Miceli McMillan R
    J Med Ethics; 2021 Oct; 47(10):701-705. PubMed ID: 33148774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychedelics and Evidence-based Psychotherapy: A Systematic Review with Recommendations for Advancing Psychedelic Therapy Research.
    Leone L; McSpadden B; DeMarco A; Enten L; Kline R; Fonzo GA
    Psychiatr Clin North Am; 2024 Jun; 47(2):367-398. PubMed ID: 38724126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelic-assisted psychotherapy: where is the psychotherapy research?
    Aday JS; Horton D; Fernandes-Osterhold G; O'Donovan A; Bradley ER; Rosen RC; Woolley JD
    Psychopharmacology (Berl); 2024 Aug; 241(8):1517-1526. PubMed ID: 38782821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychedelics and Psychotherapy.
    Nayak S; Johnson MW
    Pharmacopsychiatry; 2021 Jul; 54(4):167-175. PubMed ID: 33285578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychedelic-assisted psychotherapy for the treatment of major depression: a synthesis of phenomenological explanations.
    Miceli McMillan R; Jordens C
    Med Health Care Philos; 2022 Jun; 25(2):225-237. PubMed ID: 35064398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action.
    Rieser NM; Herdener M; Preller KH
    Curr Top Behav Neurosci; 2022; 56():187-211. PubMed ID: 34910289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments.
    Greenway KT; Garel N; Jerome L; Feduccia AA
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):655-670. PubMed ID: 32478631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique.
    Mosurinjohn S; Roseman L; Girn M
    Front Psychiatry; 2023; 14():1077311. PubMed ID: 37181886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy.
    Hendricks PS
    Int Rev Psychiatry; 2018 Aug; 30(4):331-342. PubMed ID: 30260256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychedelics: Where we are now, why we got here, what we must do.
    Belouin SJ; Henningfield JE
    Neuropharmacology; 2018 Nov; 142():7-19. PubMed ID: 29476779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelic Psychiatry: Preparing for Novel Treatments Involving Altered States of Consciousness.
    Holoyda B
    Psychiatr Serv; 2020 Dec; 71(12):1297-1299. PubMed ID: 33050796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of recreational psychedelic substance use experiences classified by substance.
    Hase A; Erdmann M; Limbach V; Hasler G
    Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model.
    Wießner I; Falchi M; Palhano-Fontes F; Feilding A; Ribeiro S; Tófoli LF
    Psychol Med; 2023 Mar; 53(4):1151-1165. PubMed ID: 34253268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ).
    Wolff M; Evens R; Mertens LJ; Schmidt C; Beck J; Rutrecht H; Cherniak AD; Gründer G; Jungaberle H
    J Psychopharmacol; 2024 May; 38(5):432-457. PubMed ID: 38742761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials.
    Herrmann Z; Earleywine M; De Leo J; Slabaugh S; Kenny T; Rush AJ
    J Psychoactive Drugs; 2023; 55(4):501-517. PubMed ID: 36127639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.